- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06571045
A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME (BRUNELLO)
En randomiserad, dubbelmaskad, multicenter, 3-arm pivotal fas 2/3-studie för att utvärdera effektiviteten och säkerheten av Intravitreal EYE103 jämfört med Intravitreal Ranibizumab (0,5 mg) hos deltagare med diabetiskt makulaödem
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig (EYE103) in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME)
In the first year, all 3 treatment groups will be treated every 4 weeks with either remigromig or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm.
Approximately 960 participants will be entered in the study.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME)
Approximately 960 participants will be entered in the study. Participants will be randomized 1:1:1 to receive low dose remigromig, high dose remigromig, or 0.5 mg ranibizumab, administered via intravitreal injection. In the first year, all 3 treatment groups will be treated every 4 weeks with either remigromig or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval (PTI) algorithm. Throughout the 2-year study, subjects will be evaluated every 4 weeks, including measurement of Early Treatment of Diabetic Retinopathy Study (ETDRS) Best-Corrected Visual Acuity (BCVA), examination by slit-lamp biomicroscopy, fundoscopy, and spectral domain optical coherence tomography (SD-OCT). Among other parameters, SD-OCT will be used to measure central subfield thickness (CST) in microns.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
- Fas 3
Kontakter och platser
Studieorter
-
-
-
CABA, Argentina, 1023
- Buenos Aires, Argentina
-
Córdoba, Argentina, X5000AAJ
- Ciudad de Cordoba, Argentina
-
-
Buenos Aires
-
CABA, Buenos Aires, Argentina, 1015
- Buenos Aires, Argentina
-
CABA, Buenos Aires, Argentina, 1120
- Buenos Aires, Argentina
-
CABA, Buenos Aires, Argentina, C1033AAW
- Buenos Aires, Argentina
-
Caba, Buenos Aires, Argentina, C1116ABA
- Caba, Buenos Aires, Argentina
-
-
Córdoba Province
-
Córdoba, Córdoba Province, Argentina, 5000
- Cordoba, Argentina
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, S2000DSK
- Santa Fe, Argentina
-
-
Sante Fe
-
Rosario, Sante Fe, Argentina, 2000
- Santa Fe, Argentina
-
-
-
-
-
Albury, Australien, 2640
- Albury, Australia
-
Parramatta, Australien, 2150
- Parramatta, Australia
-
Sydney, Australien, 2000
- Sydney, Australia
-
-
New South Wales
-
Sydney, New South Wales, Australien, 2000
- Sydney Retina Clinic
-
Sydney, New South Wales, Australien, 2135
- Sydney, Australia
-
-
-
-
-
Medellín, Colombia, 50016
- Medellin, Colombia
-
-
Antioquia
-
Medellín, Antioquia, Colombia, 50021
- Medellin, Colombia
-
-
Atlántico
-
Barranquilla, Atlántico, Colombia, 80002
- Barranquilla, Colombia
-
-
Columbia
-
Bogotá, Columbia, Colombia, 110231
- Bogota, Columbia
-
-
Valle del Cauca Department
-
Cali, Valle del Cauca Department, Colombia, 760042
- Cali, Colombia
-
-
-
-
-
Créteil, Frankrike, 94010
- Creteil, France
-
Lyon, Frankrike, 69004
- Lyon, France
-
Marseille, Frankrike, 13008
- Marseille, France
-
Paris, Frankrike, 75006
- Paris, France
-
Paris, Frankrike, 75015
- Paris, France
-
Paris, Frankrike, 75019
- Paris, France
-
Saint-Cyr-sur-Loire, Frankrike, 37540
- Saint Cyr sur Loire, France
-
-
Cedex
-
Dijon, Cedex, Frankrike, 21079
- Cedex, France
-
-
-
-
Arizona
-
Scottsdale, Arizona, Förenta staterna, 85255
- Scottsdale
-
-
Arkansas
-
Fayetteville, Arkansas, Förenta staterna, 72703
- Fayetteville, Arkansas
-
Springdale, Arkansas, Förenta staterna, 72764
- Springdale, Arkansas
-
-
California
-
Bakersfield, California, Förenta staterna, 93309
- Bakersfield, CA
-
Glendale, California, Förenta staterna, 91204
- Glendale, CA
-
Modesto, California, Förenta staterna, 95356
- Modesto, CA
-
Mountain View, California, Förenta staterna, 94040
- Mountain View, CA
-
Redlands, California, Förenta staterna, 92374
- Redlands, CA
-
Sacramento, California, Förenta staterna, 95825
- Sacramento, CA
-
Sacramento, California, Förenta staterna, 95841
- Sacramento, CA
-
Santa Ana, California, Förenta staterna, 92705
- Santa Ana
-
-
Colorado
-
Colorado Springs, Colorado, Förenta staterna, 80909
- Colorado Springs, CO
-
Denver, Colorado, Förenta staterna, 80210
- Denver, Colorado
-
-
Connecticut
-
Danbury, Connecticut, Förenta staterna, 06810
- Danbury, CT
-
Manchester, Connecticut, Förenta staterna, 06042
- Manchester, CT
-
Waterford, Connecticut, Förenta staterna, 06385
- Waterford,CT
-
-
Florida
-
Deerfield Beach, Florida, Förenta staterna, 33064
- Deerfield Beach, FL
-
Fort Lauderdale, Florida, Förenta staterna, 33308
- Fort Lauderdale, FL
-
Fort Myers, Florida, Förenta staterna, 33912
- Fort Myers,FL
-
Gainesville, Florida, Förenta staterna, 32607
- Gainesville, FL
-
Orlando, Florida, Förenta staterna, 32806
- Orlando, Florida
-
Plantation, Florida, Förenta staterna, 33324
- Plantation, FL
-
Sarasota, Florida, Förenta staterna, 34232
- Sarasota, FL
-
St. Petersburg, Florida, Förenta staterna, 33711
- Saint Petersburg, FL
-
Tallahassee, Florida, Förenta staterna, 32308
- Tallahassee, FL
-
Tampa, Florida, Förenta staterna, 33609-4614
- Tampa, FL
-
Tampa, Florida, Förenta staterna, 33617
- Tampa, FL
-
Winter Haven, Florida, Förenta staterna, 33880
- Winter Haven, FL
-
-
Illinois
-
Lemont, Illinois, Förenta staterna, 60439
- Lemont, IL
-
Springfield, Illinois, Förenta staterna, 62702
- Springfield, Illinois
-
-
Iowa
-
West Des Moines, Iowa, Förenta staterna, 50266
- West Des Moines, IA
-
-
Kansas
-
Lenexa, Kansas, Förenta staterna, 66215
- Lenexa, Kansas
-
Wichita, Kansas, Förenta staterna, 67214
- Wichita, Kansas
-
-
Maine
-
Portland, Maine, Förenta staterna, 04101
- Portland, Maine
-
-
Maryland
-
Hagerstown, Maryland, Förenta staterna, 21740
- Hagerstown, MD
-
-
Massachusetts
-
Springfield, Massachusetts, Förenta staterna, 01107
- Springfield,MA
-
-
Michigan
-
Grand Rapids, Michigan, Förenta staterna, 49546
- Grand Rapids, Michigan
-
-
Minnesota
-
Minneapolis, Minnesota, Förenta staterna, 55435
- Minneapolis, MN
-
-
Mississippi
-
Madison, Mississippi, Förenta staterna, 39110
- Madison, MS
-
-
New Jersey
-
Bloomfield, New Jersey, Förenta staterna, 07003
- Bloomfield, NJ
-
Cherry Hill, New Jersey, Förenta staterna, 08034
- Cherry Hill, NJ
-
-
New York
-
Liverpool, New York, Förenta staterna, 13088
- Liverpool, NY
-
Oceanside, New York, Förenta staterna, 11572
- Oceanside, NY
-
Rochester, New York, Förenta staterna, 14620
- Rochester, NY
-
-
North Carolina
-
Asheville, North Carolina, Förenta staterna, 28803
- Asheville, NC
-
Hickory, North Carolina, Förenta staterna, 28602
- Hickory, NC
-
Wake Forest, North Carolina, Förenta staterna, 27587
- Wake Forest, MC
-
Winston-Salem, North Carolina, Förenta staterna, 27103
- Winston Salem, NC
-
-
Ohio
-
Cleveland, Ohio, Förenta staterna, 44122
- Cleveland, Ohio
-
Cleveland, Ohio, Förenta staterna, 44130
- Cleveland, OH
-
Youngstown, Ohio, Förenta staterna, 44505
- Youngstown, Ohio
-
-
Oklahoma
-
Edmond, Oklahoma, Förenta staterna, 73013
- Edmond, OK
-
-
Oregon
-
Portland, Oregon, Förenta staterna, 97221
- Portland, OR
-
Springfield, Oregon, Förenta staterna, 97477
- Springfield, Oregon
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Förenta staterna, 18017
- Bethlehem, PA
-
Erie, Pennsylvania, Förenta staterna, 16507
- Erie, PA
-
-
South Carolina
-
Beaufort, South Carolina, Förenta staterna, 29902
- Beaufort, SC
-
Florence, South Carolina, Förenta staterna, 29501
- Florence, SC
-
Ladson, South Carolina, Förenta staterna, 29456
- Ladson, SC
-
West Columbia, South Carolina, Förenta staterna, 29169
- West Columbia, SC
-
-
Tennessee
-
Germantown, Tennessee, Förenta staterna, 38138
- Germantown, TN
-
Hixson, Tennessee, Förenta staterna, 37343
- Hixson, Tennessee
-
Johnson City, Tennessee, Förenta staterna, 37604
- Johnson City, Tennessee
-
Knoxville, Tennessee, Förenta staterna, 37922
- Knoxville, TN
-
Nashville, Tennessee, Förenta staterna, 37203
- Nashville, TN
-
-
Texas
-
Abilene, Texas, Förenta staterna, 79606
- Abilene, TX
-
Amarillo, Texas, Förenta staterna, 79109
- Amarillo, TX
-
Amarillo, Texas, Förenta staterna, 79106
- Amarillo, TX
-
Arlington, Texas, Förenta staterna, 76012
- Arlington, TX
-
Austin, Texas, Förenta staterna, 78705
- Austin, TX
-
Beaumont, Texas, Förenta staterna, 77707
- Beaumont, TX
-
Bellaire, Texas, Förenta staterna, 77401
- Bellaire, TX
-
Dallas, Texas, Förenta staterna, 75231
- Dallas, TX
-
Fort Worth, Texas, Förenta staterna, 76104
- Fort Worth, TX
-
Katy, Texas, Förenta staterna, 77494
- Katy, TX
-
Plano, Texas, Förenta staterna, 75075
- Plano, TX
-
Round Rock, Texas, Förenta staterna, 78681
- Round Rock, TX
-
San Antonio, Texas, Förenta staterna, 78240
- San Antonio, TX
-
Schertz, Texas, Förenta staterna, 78154
- Schertz, Texas
-
The Woodlands, Texas, Förenta staterna, 77384
- The Woodlands, TX
-
Willow Park, Texas, Förenta staterna, 76087
- Willow Park, TX
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84107
- Salt Lake City, Utah
-
-
Virginia
-
Lynchburg, Virginia, Förenta staterna, 24502
- Lynchburg, VA
-
Richmond, Virginia, Förenta staterna, 23235
- Richmond, Virginia
-
-
Washington
-
Spokane, Washington, Förenta staterna, 99204
- Spokane, WA
-
-
-
-
-
Be’er Ya‘aqov, Israel, 70300
- Beer Yakov, Israel
-
Haifa, Israel, 3436212
- Haifa, Israel
-
Jerusalem, Israel, 9112001
- Jerusalem, Israel
-
Petah Tikva, Israel, 49100
- Petah Tikva, Israel
-
Rehovot, Israel, 76100
- Rehovot, Israel
-
Tel Aviv, Israel, 6423906
- Tel Aviv, Israel
-
-
-
-
-
Bologna, Italien, 40138
- Bologna, Italy
-
Florence, Italien, 50139
- Firenze, Italy
-
Milan, Italien, 20122
- Milano, Italy
-
Milan, Italien, 20132
- Milano, Italy
-
Milan, Italien, 20157
- Milano, Italy
-
Roma, Italien, 00168
- Roma, Italy
-
Rome, Italien, 81.00133
- Rome, Italy
-
Udine, Italien, 33100
- Udine, Italy
-
-
-
-
-
Osijek, Kroatien, 31000
- Osijek, Croatia
-
-
-
-
-
Riga, Lettland, LV1002
- Riga, Latvia
-
Riga, Lettland, LV1006
- Riga, Latvia
-
-
-
-
-
Bialystok, Polen, 15-866
- Bialystok, Poland
-
Bydgoszcz, Polen, 85-309
- Bydgoszcz, Poland
-
Bydgoszcz, Polen, 85-631
- Bydgoszcz, Poland
-
Gdansk, Polen, 80-809
- Gdansk, Poland
-
Katowice, Polen, 40-594
- Katowice, Poland
-
Krakow, Polen, 31-501
- Krakow, Poland
-
Olsztyn, Polen, 10-424
- Olsztyn, Poland
-
Tarnowskie Góry, Polen, 42-600
- Tarnowskie Gory, Poland
-
-
Gdansk
-
Gdansk, Gdansk, Polen, 80-809
- Gdansk, Poland
-
-
-
-
-
Coimbra, Portugal, 3000-548
- Coimbra, Portugal
-
Coimbra, Portugal, 3030-163
- Coimbra, Portugal
-
Porto, Portugal, 4200-319
- Porto, Portugal
-
-
-
-
PR
-
Arecibo, PR, Puerto Rico, 00612
- Arecibo, PR
-
-
-
-
-
Trebišov, Slovakien, 075 01
- Trebisov, Slovakia
-
Trenčín, Slovakien, 911 01
- Trencin, Slovakia
-
Žilina, Slovakien, 012 07
- Zilina, Slovakia
-
-
-
-
-
Barcelona, Spanien, 08035
- Barcelona, Spain
-
Barcelona, Spanien, 08021
- Barcelona, Spain
-
Barcelona, Spanien, 08022
- Barcelona, Spain
-
Barcelona, Spanien, 08195
- Barcelona, Spain
-
Santiago de Compostela, Spanien, 15706
- Santiago de Compostela, Spain
-
Seville, Spanien, 41009
- Sevilla, Spain
-
Zaragoza, Spanien, 50009
- Zaragoza, Spain
-
-
Valencia
-
Burjassot, Valencia, Spanien, 46100
- Valencia, Spain
-
-
-
-
-
Bradford, Storbritannien, BD9 6RJ
- Bradford, United Kingdom
-
Bristol, Storbritannien, BS1 2LX
- Bristol, UK
-
Liverpool, Storbritannien, L7 8YA
- Liverpool, United Kingdom
-
Sunderland, Storbritannien, SR2 9HP
- Sunderland, United Kingdom
-
Wolverhampton, Storbritannien, WV10 0QP
- Wolverhamptom, United Kingdom
-
-
Middlesex
-
London, Middlesex, Storbritannien, NW10 7NS
- London, UK
-
-
UnitedKingdom
-
York, UnitedKingdom, Storbritannien, YO10 4DZ
- York, United Kingdom
-
-
-
-
-
Mladá Boleslav, Tjeckien, 293 01
- Mlada Boleslav, Czechia
-
Náchod, Tjeckien, 547 01
- Nachod, Czechia
-
Prague, Tjeckien, 1150/50
- Prague, Czechia
-
Prague, Tjeckien
- Prague, Czechia
-
-
-
-
Turkey
-
Ankara, Turkey, Turkiet (Türkiye), 06230
- Ankara, Turkey
-
Ankara, Turkey, Turkiet (Türkiye), 06490
- Ankara, Turkey
-
Balçova, Turkey, Turkiet (Türkiye), 35330
- Balcova, Turkey
-
-
-
-
-
Frankfurt, Tyskland, 60590
- Frankfurt, Germany
-
Hanover, Tyskland, 30625
- Hanover, Germany
-
München, Tyskland, 80336
- Munchen, Germany
-
Münster, Tyskland, 48145
- Munster, Germany
-
-
-
-
-
Budapest, Ungern, H-1062
- Budapest, Hungary
-
Budapest, Ungern, H-1085
- Budapest, Hungary
-
Budapest, Ungern, H-1106
- Budapest, Hungary
-
Budapest, Ungern, H-1133
- Budapest, Hungry
-
Debrecen, Ungern, H-4032
- Debrecen, Hungary
-
Pécs, Ungern, H-7621
- Pecs, Hungary
-
Szeged, Ungern, H-6720
- Szeged, Hungary
-
Zalaegerszeg, Ungern, 8900
- Zalaegerszeg, Hungary
-
-
-
-
-
Graz, Österrike, 8036
- Graz, Austria
-
Innsbruck, Österrike, 6020
- Innsbruck, Austria
-
Vienna, Österrike, 1090
- Vienna, Austria
-
Vienna, Österrike, 1140
- Vienna, Austria
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity
- Be male or female ≥18 years of age.
- Have type 1 or type 2 diabetes mellitus and a hemoglobin A1c (HbA1c) of ≤12%.
- Have a decrease in vision in the study eye determined by the investigator to be primarily the result of diabetic macular edema (DME).
Exclusion Criteria:
-
Be pregnant or breastfeeding
-
History of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of Screening
-
Have any treatment for complications of cataract surgery with steroids or yttrium aluminum garnet (YAG) laser capsulotomy within 90 days of Screening
-
Are currently using drugs with known retinal toxicity (e.g., Hydroxychloroquine, pentosan polysulfate sodium, and amiodarone)
-
If treatment-experienced for DME have a history of any of the following treatments within the noted time windows:
- Have had prior treatment in the study eye with 8 mg aflibercept (EYLEA HD) or faricimab (VABYSMO) within 120 days prior to the Screening visit in the study eye
- Have had an IVT with other anti-VEGF treatments (ranibizumab, bevacizumab, aflibercept [2 mg], brolucizumab, pegaptanib sodium) in the study eye within 90 days of the Screening visit
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Remigromig Low Dose Treatment Arm
Remigromig Low Dose Treatment Arm |
Remigromig is a humanized antibody formulated for intravitreal administration
Andra namn:
|
|
Experimentell: Remigromig High Dose Treatment Arm
Remigromig High Dose Treatment Arm |
Remigromig is a humanized antibody formulated for intravitreal administration
Andra namn:
|
|
Aktiv komparator: Ranibizumab Treatment Arm
Ranibizumab Treatment Arm |
Ranibizumab is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with diabetic macular edema
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change from baseline in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart
Tidsram: Baseline and Week 52
|
The change from baseline in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart will be presented. |
Baseline and Week 52
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change from Baseline in Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) at Week 52
Tidsram: Baseline and Week 52
|
The change from baseline in Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) at Week 52 will be presented. |
Baseline and Week 52
|
|
Superiority Hypothesis: Change from Baseline in ETDRS BCVA at Week 52
Tidsram: Baseline and Week 52
|
The Superiority Hypothesis: change from baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS) Best-Corrected Visual Acuity (BCVA) at Week 52 will be presented. |
Baseline and Week 52
|
|
Time to Absence of Diabetic Macular Edema (DME)
Tidsram: Up to approximately Week 104
|
The time to absence of Diabetic Macular Edema (DME) defined as Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) of <300 μm will be presented. |
Up to approximately Week 104
|
|
Time to Gaining ≥15 ETDRS letters
Tidsram: Up to approximately Week 52
|
The time to gaining ≥15 letters on the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart will be presented. |
Up to approximately Week 52
|
|
Proportion of Participants with Resolution of Macular Leakage on FA at Week 24
Tidsram: Up to approximately Week 24
|
The proportion of participants with resolution of macular leakage on fluorescein angiography (FA), defined as 0 to 1 mm^2, at Week 24 will be presented. |
Up to approximately Week 24
|
|
Proportion of Participants Without Intraretinal and Subretinal Fluid at the Foveal Center on OCT at Week 52
Tidsram: Up to approximately Week 52
|
The proportion of participants without intraretinal and subretinal fluid at the foveal center on Optical Coherence Tomography (OCT) at Week 52 will be presented. |
Up to approximately Week 52
|
|
Change from Baseline in Focal Area Zone (FAZ) area on fluorescein angiography (FA) at Week 52
Tidsram: Baseline and Week 52
|
The change from baseline in Focal Area Zone (FAZ) area on fluorescein angiography (FA) at Week 52 will be presented. |
Baseline and Week 52
|
|
Proportion of Participants Achieving 20/40 or Better BCVA at Week 52
Tidsram: Up to approximately Week 52
|
The proportion of participants who achieve 20/40 or better Best-Corrected Visual Acuity (BCVA) at Week 52 will be presented. |
Up to approximately Week 52
|
|
Number of Participants Who Experience an Ocular and/or Systemic Adverse Event (AE)
Tidsram: Up to approximately 104 Weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an ocular and/or systemic AE will be reported. |
Up to approximately 104 Weeks
|
|
Number of Participants Who Experience an Ocular and/or Systemic Serious Adverse Event (SAE)
Tidsram: Up to approximately 104 Weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an ocular and/or systemic serious adverse event (SAE) will be reported. |
Up to approximately 104 Weeks
|
|
Number of Participants Who Discontinue Study Treatment Due to an AE
Tidsram: Up to approximately 104 Weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported. |
Up to approximately 104 Weeks
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Charles Miller, MD PhD, EyeBiotech Ltd.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- EYE-RES-102
- MK-3000-001 (Annan identifierare: MSD)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .